News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter

Daval International Limited Release: Results From an Exploratory Clinical Trial of AIMSPRO in Amyotrophic Lateral Sclerosis (ALS) to be Presented at AAN Annual Meeting

3/12/2013 10:11:06 AM

Eastbourne, UK – Daval International, the emerging life sciences company focused on the development of novel treatments for serious unmet medical needs, announces that Professor Syed Haq, the Company’s Chief Scientific Officer, will present a poster at the 65th Annual Meeting of the American Academy of Neurology (AAN) taking place from March 16–23, 2013, at the San Diego Convention Center, San Diego, CA, USA.

Professor Haq will present data from a 21 patient, single arm, multi-centre, multi-national open-label, exploratory clinical trial examining the potential of subcutaneous injections of hyperimmune caprine sera (HICS, AIMSPRO®) as a novel treatment for ALS. He will also present supportive data from a study of the drug in a preclinical animal model of the disease.

The AAN annual meeting is the world’s largest international congress of neurologists and neuroscience professionals.

The title, timing and location of Professor Haq’s presentation are:

Title: The role of stabilized neuropeptides derived from hyperimmune caprine sera (HICS) in motor neuron disease – implications for a novel therapeutic strategy

Presented by: Professor Syed B. Haq, London, England

Session: Emerging Science Poster Presentations – Poster Session 4


Date: Wednesday, March 20, 2013

Presentation time: 7:30 am to 12:00 pm PDT

The abstract will be available for download on Daval International’s website by March 21, 2013, 07:00 am GMT, see

For further information please contact:

Daval International Ltd

James Shotton +1 303 588 5881 or +44 (0)7739 648401

Chief Executive

NM Rothschild

Julian Hudson +44 (0) 20 7280 5000

FTI Consulting

Julia Phillips / Simon Conway +44 (0)20 7831 3113


AIMSPRO® (Hyperimmune Caprine Sera, HICS) is a proprietary, purified, protein–multi-peptide conjugate complex being developed as a novel, first-in-class biological treatment for a number of immune diseases where regulation and stabilisation of the immune system is required. It is believed that the drug has a unique mechanism of action that supports its broad potential application in neuro-degenerative diseases. AIMSPRO has been granted a Specials License by the UK's MHRA and is also available in Australia under Categories A and B of the TGA's Special Access Scheme.

About Daval International Limited

Daval International Limited is an emerging life sciences company focused on the development of novel treatments for serious unmet medical needs through a combination of innovation, dedication, skilled science, entrepreneurship and partnership. From its inception in 2000, the management team of Daval have had a vision of making available effective treatments that noticeably improve the quality of life of patients suffering from the most serious debilitating neuro-degenerative, inflammatory and autoimmune diseases and to offer a choice over and above some of the disease modifying treatments available currently.

Read at

comments powered by Disqus